Bai Y - Search Results

1

[Blocking Adenosine/A2AR Pathway for Cancer Therapy].

Liu J, Shi Y, Liu X, Zhang D, Bai Y, Xu Y, Wang M. Liu J, et al. Among authors: bai y. Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):460-467. doi: 10.3779/j.issn.1009-3419.2022.102.24. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35899442 Free PMC article. Review. Chinese.

2

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.

Bai Y, Zhang X, Zheng J, Liu Z, Yang Z, Zhang X. Bai Y, et al. J Exp Clin Cancer Res. 2022 Oct 14;41(1):302. doi: 10.1186/s13046-022-02511-1. J Exp Clin Cancer Res. 2022. PMID: 36229853 Free PMC article.

3

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.

Li J, Davies BR, Han S, Zhou M, Bai Y, Zhang J, Xu Y, Tang L, Wang H, Liu YJ, Yin X, Ji Q, Yu DH. Li J, et al. Among authors: bai y. J Transl Med. 2013 Oct 2;11:241. doi: 10.1186/1479-5876-11-241. J Transl Med. 2013. PMID: 24088382 Free PMC article.

4

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.

Zhang Q, Zhang XC, Yang JJ, Yang ZF, Bai Y, Su J, Wang Z, Zhang Z, Shao Y, Zhou Q, Kang J, Ke EE, Zhang YC, Dong ZY, Chen ZH, Tu HY, Zhong WZ, Yang XN, Wu YL. Zhang Q, et al. Among authors: bai y. J Thorac Oncol. 2018 Sep;13(9):1415-1421. doi: 10.1016/j.jtho.2018.05.024. Epub 2018 May 30. J Thorac Oncol. 2018. PMID: 29857056 Free article.

5

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.

Li A, Yang JJ, Zhang XC, Zhang Z, Su J, Gou LY, Bai Y, Zhou Q, Yang Z, Han-Zhang H, Zhong WZ, Chuai S, Zhang Q, Xie Z, Gao H, Chen H, Wang Z, Wang Z, Yang XN, Wang BC, Gan B, Chen ZH, Jiang BY, Wu SP, Liu SY, Xu CR, Wu YL. Li A, et al. Among authors: bai y. Clin Cancer Res. 2017 Aug 15;23(16):4929-4937. doi: 10.1158/1078-0432.CCR-16-3273. Epub 2017 Apr 10. Clin Cancer Res. 2017. PMID: 28396313

6

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.

Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, Xu Y, Yin X, Bai Y, Rabbie S, Kim DW, Ahn MJ, Yang JC, Zhang X. Yang Z, et al. Among authors: bai y. Sci Transl Med. 2016 Dec 7;8(368):368ra172. doi: 10.1126/scitranslmed.aag0976. Sci Transl Med. 2016. PMID: 27928026

7

EGFR G796D mutation mediates resistance to osimertinib.

Zheng D, Hu M, Bai Y, Zhu X, Lu X, Wu C, Wang J, Liu L, Wang Z, Ni J, Yang Z, Xu J. Zheng D, et al. Among authors: bai y. Oncotarget. 2017 Jul 25;8(30):49671-49679. doi: 10.18632/oncotarget.17913. Oncotarget. 2017. PMID: 28572531 Free PMC article.

8

Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?

Zhang J, Zhang L, Yan Y, Li S, Xie L, Zhong W, Lv J, Zhang X, Bai Y, Cheng Z. Zhang J, et al. Among authors: bai y. Drug Metab Dispos. 2015 Mar;43(3):411-7. doi: 10.1124/dmd.114.061820. Epub 2014 Dec 29. Drug Metab Dispos. 2015. PMID: 25547867

9

Ru Single Atom Dispersed on MoS₂/MXene for Enhanced Sulfur Reduction Reaction in Lithium-Sulfur Batteries.

Bai Y, Nguyen TT, Song H, Chu R, Tran DT, Kim NH, Lee JH. Bai Y, et al. Small. 2024 May 25:e2402074. doi: 10.1002/smll.202402074. Online ahead of print. Small. 2024. PMID: 38794990

10

Acoustofluidic manipulation for submicron to nanoparticles.

Wei W, Wang Z, Wang B, He X, Wang Y, Bai Y, Yang Q, Pang W, Duan X. Wei W, et al. Among authors: bai y. Electrophoresis. 2024 May 25. doi: 10.1002/elps.202400062. Online ahead of print. Electrophoresis. 2024. PMID: 38794970 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,711 results

Search Page